PUPeyton Uhl

Peyton Uhl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peyton Uhl has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Brian P. Johnson

    Department of Biomedical Engineering University of Wisconsin‐Madison 1415 Engineering Drive Madison WI 53706 USA

    1 shared publication
  • Cheryl Soref

    Department of Orthopedics and Rehabilitation University of Wisconsin‐Madison 1111 Highland Ave., WIMR 5418 Madison WI 53705 USA

    1 shared publication
  • Daniel Mamott

    Morgridge Institute for Research 330 N Orchard St Madison WI 53715 USA

    1 shared publication
  • David J. Beebe

    Department of Biomedical Engineering University of Wisconsin‐Madison 1415 Engineering Drive Madison WI 53706 USA

    1 shared publication
  • Elizabeth Torr

    Department of Orthopedics, University of Wisconsin, Madison, WI 53705, USA

    1 shared publication
  • Gaurav Kaushik

    Department of Orthopedics and Rehabilitation University of Wisconsin‐Madison 1111 Highland Ave., WIMR 5418 Madison WI 53705 USA

    1 shared publication

Latest Publications

  • Engineered Perineural Vascular Plexus for Modeling Developmental Toxicity

    by Gaurav Kaushik, Kartik Gupta, Victoria Harms, Elizabeth Torr, Jonathan Evans, Hunter J. Johnson, Cheryl Soref, Suehelay Acevedo‐Acevedo, Jessica Antosiewicz‐Bourget, Daniel Mamott, et al.

    There is a vital need to develop in vitro models of the developing human brain to recapitulate the biological effects that toxic compounds have on the brain. To model perineural vascular plexus (PNVP) in vitro, which is a key stage in embryonic development, human embryonic stem cells (hESC)‐derived endothelial cells (ECs), neural progenitor cells, and microglia (MG) with primary pericytes (PCs) in synthetic hydrogels in a custom‐designed microfluidics device are cocultured. The formation of a vascular plexus that includes networks of ECs (CD31+, VE‐cadherin+), MG (IBA1+), and PCs (PDGFRβ+), and an overlying neuronal layer that includes differentiated neuronal cells (βIII Tubulin+, GFAP+) and radial glia (Nestin+, Notch2NL+), are characterized. Increased brain‐derived neurotrophic factor secretion and differential metabolite secretion by the vascular plexus and the neuronal cells over time are consistent with PNVP functionality. Multiple concentrations of developmental toxicants (teratogens, microglial disruptor, and vascular network disruptors) significantly reduce the migration of ECs and MG toward the neuronal layer, inhibit formation of the vascular network, and decrease vascular endothelial growth factor A (VEGFA) secretion. By quantifying 3D cell migration, metabolic activity, vascular network disruption, and cytotoxicity, the PNVP model may be a useful tool to make physiologically relevant predictions of developmental toxicity.